RxDoctor Payments Data

Pacifico Magahis, MD

Gastroenterology · Brick, NJNPI 1659469005

Payments from drug & device makers

$4,101in general payments, 2019–2025

Across 269 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$763
  • Gilead$419
  • Johnson & Johnson$371
  • Pfizer$318
  • E.r. Squibb & Sons, L.L.C.$315
  • plus $602 from 18 others

What the payments were for

  • Speaking & faculty fees$200%
  • Grants$200%
  • Food & beverage$4,06199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,101 in reported general payments places this provider in the 60th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$291,543
Medicare patients
966
Services billed
2,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$559,990
CreonLipase/Protease/Amylase33$95,937
LinzessLinaclotide116$71,499
Mesalamine37$28,151
ViberziEluxadoline14$21,877
ZenpepLipase/Protease/Amylase12$20,972
Alosetron Hcl12$13,654
Pantoprazole Sodium848$12,847
Sucralfate36$8,132
Dicyclomine Hcl231$6,171
Dexlansoprazole DrDexlansoprazole15$6,110
Lubiprostone34$5,450
CholestyramineCholestyramine (With Sugar)72$5,401
Mesalamine ErMesalamine15$2,564
Esomeprazole Magnesium72$2,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$371$559,99021 claims
AbbVieCreon, Linzess, Viberzi$1,313$189,312163 claims
Aimmune Therapeutics, Inc.Zenpep$32$20,97212 claims
Ferring Pharmaceuticals Inc.Clenpiq$13$1,89211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →